NRIX
Company Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 83.98M | 54.55M | 76.99M | 38.63M | 29.75M | 17.82M | 31.11M | 37.45M |
| Net Income | (264.46M) | (193.57M) | (143.95M) | (180.36M) | (117.19M) | (43.24M) | (21.70M) | (9.43M) |
| EPS | -3.05 | -2.88 | -2.65 | -3.71 | -2.73 | -2.76 | -0.56 | -0.59 |
| Free Cash Flow | (263.47M) | (181.86M) | (89.77M) | (172.05M) | (90.03M) | (4.63M) | (1.05M) | (33.27M) |
| FCF / Share | -3.04 | -2.71 | -1.65 | -3.54 | -2.10 | -0.30 | -0.03 | -2.07 |
| Operating CF | (249.47M) | (172.58M) | (81.36M) | (159.81M) | (84.36M) | (80,000) | 601,000 | (31.68M) |
| Total Assets | 688.13M | 669.34M | 355.60M | 416.76M | 476.77M | 396.34M | 44.05M | 45.40M |
| Total Debt | 55.73M | 28.30M | 30.61M | 11.96M | 13.04M | 0 | 0 | 0 |
| Cash & Equiv | 246.96M | 110.00M | 54.63M | 64.47M | 80.51M | 119.36M | 34.82M | 25.59M |
| Book Value | 538.75M | 526.99M | 200.49M | 303.70M | 342.30M | 290.27M | (57.71M) | (36.85M) |
| Return on Equity | -0.49 | -0.37 | -0.72 | -0.59 | -0.34 | -0.15 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.25M | 13.58M | 7.89M | 44.06M | 18.45M | 13.28M | 12.59M | 12.09M | 16.59M | 15.16M | 18.47M | 30.68M |
| Net Income | (87.17M) | (78.22M) | (86.42M) | (43.46M) | (56.35M) | (58.55M) | (48.96M) | (44.55M) | (41.52M) | (41.96M) | (36.98M) | (24.28M) |
| EPS | -0.79 | -0.82 | -1.03 | -0.52 | -0.67 | -0.75 | -0.67 | -0.71 | -0.76 | -0.77 | -0.68 | -0.40 |
| Free Cash Flow | (72.96M) | (72.96M) | (60.10M) | (65.84M) | (64.57M) | (50.86M) | (44.52M) | (41.64M) | (44.84M) | 24.10M | (43.59M) | (19.55M) |
| FCF / Share | -0.66 | -0.77 | -0.71 | -0.78 | -0.77 | -0.65 | -0.61 | -0.67 | -0.82 | 0.44 | -0.80 | -0.36 |
| Operating CF | (71.91M) | (67.83M) | (57.38M) | (63.16M) | (61.09M) | (48.75M) | (42.18M) | (39.70M) | (41.95M) | 26.69M | (41.13M) | (18.47M) |
| Total Assets | 636.13M | 688.13M | 522.47M | 591.55M | 615.04M | 669.34M | 513.60M | 511.03M | 312.67M | 355.60M | 308.19M | 350.62M |
| Total Debt | 58.66M | 55.73M | 56.49M | 51.93M | 26.62M | 28.30M | 27.14M | 28.82M | 29.16M | 30.61M | 8.00M | 9.34M |
| Cash & Equiv | 71.19M | 246.96M | 78.44M | 84.26M | 75.92M | 110.00M | 99.04M | 116.79M | 49.81M | 54.63M | 42.30M | 58.96M |
| Book Value | 480.89M | 538.75M | 372.25M | 447.60M | 480.92M | 526.99M | 376.86M | 370.69M | 168.75M | 200.49M | 233.82M | 259.92M |
| Return on Equity | -0.18 | -0.15 | -0.23 | -0.10 | -0.12 | -0.11 | -0.13 | -0.12 | -0.25 | -0.21 | -0.16 | -0.09 |
